Cediranib
Cediranib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against vascular endothelial growth factor receptor 1, mast/stem cell growth factor receptor Kit, vascular endothelial growth factor receptor 3, platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha. In addition, it is known to target receptor-type tyrosine-protein kinase FLT3 and macrophage colony-stimulating factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 7 | 4 | — | 1 | 14 |
| Glioblastoma | D005909 | EFO_0000515 | — | 4 | 5 | 1 | — | — | 9 |
| Colorectal neoplasms | D015179 | — | — | 4 | 6 | 2 | — | — | 9 |
| Fallopian tube neoplasms | D005185 | — | — | 2 | 5 | 2 | — | — | 7 |
| Endometrioid carcinoma | D018269 | — | — | 1 | 5 | 2 | — | — | 6 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 3 | 2 | 2 | — | — | 6 |
| Acinar cell carcinoma | D018267 | — | — | — | 3 | 2 | — | — | 4 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 15 | 3 | — | — | 1 | 19 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 6 | — | — | 1 | 9 |
| Non-small-cell lung carcinoma | D002289 | — | — | 4 | 4 | — | — | — | 8 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 4 | — | — | — | 6 |
| Gliosarcoma | D018316 | — | — | 3 | 3 | — | — | — | 5 |
| Prostatic neoplasms | D011471 | — | C61 | — | 4 | — | — | — | 4 |
| Melanoma | D008545 | — | — | 3 | 1 | — | — | — | 4 |
| Alveolar soft part sarcoma | D018234 | — | — | — | 3 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 2 | — | — | — | 3 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | 2 | — | — | — | 3 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rectal neoplasms | D012004 | — | — | 3 | — | — | — | — | 3 |
| Colonic neoplasms | D003110 | — | C18 | 2 | — | — | — | — | 2 |
| Ependymoma | D004806 | — | — | 2 | — | — | — | — | 2 |
| Astrocytoma | D001254 | EFO_0000271 | — | 2 | — | — | — | — | 2 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 1 | — | — | — | — | 1 |
Show 26 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Cediranib |
| INN | cediranib |
| Description | 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline is an aromatic ether. |
| Classification | Small molecule |
| Drug class | angiogenesis inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 288383-20-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL491473 |
| ChEBI ID | — |
| PubChem CID | 9933475 |
| DrugBank | — |
| UNII ID | NQU9IPY4K9 (ChemIDplus, GSRS) |
Target
Agency Approved
FLT1
FLT1
KIT
KIT
FLT4
FLT4
PDGFRB
PDGFRB
KDR
KDR
PDGFRA
PDGFRA
Organism
Homo sapiens
Gene name
FLT1
Gene synonyms
FLT, FRT, VEGFR1
NCBI Gene ID
Protein name
vascular endothelial growth factor receptor 1
Protein synonyms
FLT, FLT-1, fms related tyrosine kinase 1, Fms-like tyrosine kinase 1, fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), Tyrosine-protein kinase FRT, Tyrosine-protein kinase receptor FLT, Vascular permeability factor receptor
Uniprot ID
Mouse ortholog
Flt1 (14254)
vascular endothelial growth factor receptor 1 (Q61517)
Alternate
FLT3
FLT3
CSF1R
CSF1R
Organism
Homo sapiens
Gene name
FLT3
Gene synonyms
CD135, FLK2, STK1
NCBI Gene ID
Protein name
receptor-type tyrosine-protein kinase FLT3
Protein synonyms
CD135, CD135 antigen, fetal liver kinase 2, Fetal liver kinase-2, FL cytokine receptor, FLK-2, FLT-3, fms related tyrosine kinase 3, Fms-like tyrosine kinase 3, growth factor receptor tyrosine kinase type III, Stem cell tyrosine kinase 1, STK-1
Uniprot ID
Mouse ortholog
Flt3 (14255)
receptor-type tyrosine-protein kinase FLT3 (Q00342)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,595 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
145 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use